trop2

Sacituzumab govitecan (IMMU-132) is a humanized ADC compound targeting Trop-2 with anticancer activity for the study of refractory, locally advanced or metastatic breast cancer and uroepithelial cancer.

Anti-TROP2 Antibody (RN927C antibody) is a human-derived monoclonal antibody (mAb) that targets TROP2. It exhibits in vitro inhibitory effects on various tumor cell lines. The Anti-TROP2 Antibody also demonstrates antitumor activity in mouse models including pancreatic PDX, ovarian PDX, lung LG0476 PDX, and triple-negative breast cancer (TNB) PDX.

Sacituzumab (hRS7) is an antibody inhibitor and a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2), serving as a component of the antibody-drug conjugate sacituzumab govitecan, used for research and treatment of TROP2-high-expressing tumors such as triple-negative breast cancer.

Datopotamab deruxtecan (DS-1062) is an antibody-drug conjugate (ADC) that targets tropomyosin 2 (TROP2) on the surface of trophoblast cells. Datopotamab deruxtecan exhibits antitumor activity by specifically binding to TROP2 and internalizing, releasing DXd to inhibit topoisomerase I (IC₅₀ = 0.31 μM), thereby inducing DNA damage and apoptosis. Datopotamab deruxtecan induces significant antibody-dependent cellular cytotoxicity in the presence of peripheral blood lymphocytes and inhibits tumor growth in xenograft models.

Sacituzumab tirumotecan (SKB264) is an antibody-drug conjugate (ADC) targeting TROP2 (trophoblast cell surface antigen 2), capable of releasing the active payload KL610023 within TROP2-positive tumour cells. an effective topoisomerase I inhibitor that induces DNA damage and leads to cell cycle arrest and apoptosis, for use in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC).

Datopotamab (CDP7657) is a TROP2-targeting antibody that is a naked antibody to Datopotamab deruxtecan and can be used to synthesize active antibody conjugators (Datopotamab deruxtecan). Datopotamab is being investigated for use in triple-negative breast cancer and non-small cell lung cancer.

PF-06478924 (PF-06664178 antibody; RN926) is a human monoclonal antibody (mAb) targeting TROP2. It is utilized in the study of advanced and metastatic solid tumors.

Sacituzumab-MMAE Anti-TROP2 Reference Antibody is produced in CHO cells and consists of a huIgG1 heavy chain and a hukappa light chain. This compound has a predicted molecular weight (MW) of 146.06 kDa.

The Anti-TROP-2 Antibody (Pr1E11) is a chimeric mouse IgG1, κ antibody targeting TROP-2 (human). Its isotype control is Mouse IgG1 kappa, Isotype Control.

Sacituzumab (Powder) is an antibody inhibitor and a humanized monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP2), serving as a component of the antibody-drug conjugate sacituzumab govitecan, used for research and treatment of TROP2-high-expressing tumors such as triple-negative breast cancer.

Tizetatug is a dual-specificity IgG1κ antibody targeting TACSTD2/TROP2, with the corresponding isotype control being HumanIgG1kappa, Isotype Control.